Kyntra Bio, Inc. (KYNB)
NASDAQ: KYNB · Real-Time Price · USD
6.76
-0.15 (-2.17%)
At close: Jun 18, 2026, 4:00 PM EDT
6.70
-0.06 (-0.89%)
After-hours: Jun 18, 2026, 4:10 PM EDT
Kyntra Bio Revenue
Kyntra Bio had revenue of $3.74M in the quarter ending March 31, 2026, with 36.47% growth. This brings the company's revenue in the last twelve months to $7.44M, up 6.35% year-over-year. In the year 2025, Kyntra Bio had annual revenue of $6.44M, down -78.26%.
Revenue (ttm)
$7.44M
Revenue Growth
+6.35%
P/S Ratio
3.65
Revenue / Employee
$218,794
Employees
34
Market Cap
27.12M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 6.44M | -23.18M | -78.26% |
| Dec 31, 2024 | 29.62M | -17.18M | -36.71% |
| Dec 31, 2023 | 46.80M | -93.93M | -66.74% |
| Dec 31, 2022 | 140.73M | -94.58M | -40.19% |
| Dec 31, 2021 | 235.31M | 58.99M | 33.46% |
| Dec 31, 2020 | 176.32M | -80.26M | -31.28% |
| Dec 31, 2019 | 256.58M | 43.62M | 20.48% |
| Dec 31, 2018 | 212.96M | 81.96M | 62.57% |
| Dec 31, 2017 | 131.00M | -52.19M | -28.49% |
| Dec 31, 2016 | 183.19M | 2.36M | 1.31% |
| Dec 31, 2015 | 180.83M | 43.23M | 31.41% |
| Dec 31, 2014 | 137.60M | 35.43M | 34.68% |
| Dec 31, 2013 | 102.17M | 36.24M | 54.96% |
| Dec 31, 2012 | 65.93M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Barinthus Biotherapeutics | 14.97M |
| Evaxion | 7.53M |
| Plus Therapeutics | 5.18M |
| Longeveron | 1.22M |
| IGC Pharma | 1.11M |
| Vistagen Therapeutics | 789.00K |
| Senti Biosciences Holdings | 38.00K |
KYNB News
- 7 days ago - Kyntra Bio Transcript: AGM 2026 - Transcripts
- 8 days ago - Kyntra Bio to present additional MATTERHORN trial data at EHA - TheFly
- 8 days ago - Kyntra Bio Presents New Roxadustat Data on Improvements in Transfusion Independence Regardless of Ring Sideroblast Status in Patients with Anemia due to Lower-Risk Myelodysplastic Syndromes - GlobeNewsWire
- 11 days ago - Kyntra Bio initiated with a Buy at Rodman & Renshaw - TheFly
- 5 weeks ago - Kyntra Bio Earnings Call Transcript: Q1 2026 - Transcripts
- 5 weeks ago - Kyntra Bio Earnings release: Q1 2026 - Filings
- 5 weeks ago - Kyntra Bio Slides: Q1 2026 - Filings
- 5 weeks ago - Kyntra Bio Quarterly report: Q1 2026 - Filings